Archive

ASH 2015: Early findings on oral therapies for relapsed/refractory DLBCL unveiled

by Thomas R. Collins: Early results show that venetoclax, a BCL-2-inhibitor, produced relatively good response rates in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.1

ASH 2015: Risk profile key in transplant decisions in non-Hodgkin lymphoma

by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.

ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results

by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.

Nicotinamide reduces risk of skin cancers

by Bruce Sylvester: Treatment with nicotinamide, a form of vitamin B3, significantly lowers the risk of common, non-melanoma skin cancer in high-risk patients, researchers reported on Oct. 21,… read more.

ASH 2015: Capitalising on recent advances in HL – R/R HL in the brentuximab vedotin era. Professor Ajay Gopal, Seattle Cancer Care Alliance, WA, USA. Dr Robert Chen, City of Hope, Duarte, CA, USA and Professor John Sweetenham, Huntsman Cancer Institute, Saltlake City, USA., discuss where they see the optimal setting for use of brentuximab vedotin following updates at ASH 2015. Click on the video image to view.

ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

ASH 2015: Brentuximab vedotin data shows durable CR five years on – is this cure? Dr Robert Chen, (City of Hope, Duarte, CA, USA) discusses the five year survival data presented at ASH; who of the CR patients to watch and wait and who to go onto allo-SCT; and whether these patients are now cured. Click video image to view.

by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.

ASH 2015: Highlights of the 57th American Hematological Society Meeting. Professor Ajay Gopal (Seattle Cancer Care Alliance), Professor Stephen Ansell (Mayo Clinic), Professor John Sweetenham (Huntsman Cancer Institute) and Professor Joseph Connors (Vancouver) share their highlights of a very busy ASH and New Year’s resolutions for their management of lymphoma in 2016. Click video image to view.

Anastrozole is effective for treating early form of breast cancer

by Bruce Sylvester: Anastrozole appears to be as effective as tamoxifen in treating ductal carcinoma in situ (DCIS), a very early form of breast cancer, and could offer… read more.

EMA Highlights: EMA gives green light for new drugs

by Gary Finnegan: Ten medicines, including a first-in-class orphan medicine for narcolepsy, were recommended for authorisation in the EU at the latest meeting of the European Medicines Agency’s Committee for Medicinal… read more.

EMA Highlights: Drug watchdog’s hands are tied in off-label prescribing spat

by Gary Finnegan: The European Medicines Agency (EMA) says its powers are limited when it comes to regulating off-label use of licensed medicines. The watchdog is at the… read more.

Resection safe and helpful for high-risk, early-stage lung cancer patients

by Bruce Sylvester: Surgical resection is a safe and helpful treatment option for a broad range of patients with early-stage lung cancer, researchers reported online on  Nov. 10,… read more.